Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: Institute of Health Services and Policy Research

Université Laval

$63,815.00

Simulating the Cost/Effectiveness of Screening Strategies for Cystic Fibrosis

FY 2010-11

Summary
The prevalence of cystic fibrosis (CF) in Canada is estimated at approximately 1/3600 live births. One Canadian out of 25 is carrying a mutation of the cystic fibrosis transmembrane regulator protein (CFTR) which predisposes to the disease. With the advent of new treatment protocols and nutritional support most CF children can now expect to live up to adulthood, with a median age of survival of 47.7 years old (CCFF 2007 report). Above all, diagnosis through newborn screening can improve the disease outcomes by allowing earlier treatment of CF complications. However, it appears that CF newborn screening (CFNS) programs are not widely implemented especially in Canada. One of the main reasons is the lack of information regarding the choice about the best, i.e., the most cost/effective, screening option. This lack of information is not surprising considering the important number of possible options that exist due to the various available tests per se (e.g. biochemical or molecular tests, or a selected panel of mutations) and the various protocols (sequential, cascade, etc.) that are possible. The aim of this one-year research project is to identify, using simulations, the most cost/effective (C/E) and cost/utile (C/U) strategies for neonatal CF screening under various conditions of prevalence of mutations and costs of tests. This study should provide to public health authorities of Quebec and other interested provinces a valuable information regarding which type of CF screening is likely to be the most C/E and C/U if introduced in their jurisdiction.
Program
Operating Grant - PA: Institute of Health Services and Policy Research
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
214996
Name
Reinharz Daniel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Services Evaluation & Interventions Research 3
Projecttitle
Simulating the Cost/Effectiveness of Screening Strategies for Cystic Fibrosis
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$63,815
Cihrequipment2
$0
Programname2
Operating Grant - PA: Institute of Health Services and Policy Research
Keyworddelim
Cost/Effectiveness; Cost/Utility; Cystic Fibrosis; Screening Strategies; Simulation
Abstract
The prevalence of cystic fibrosis (CF) in Canada is estimated at approximately 1/3600 live births. One Canadian out of 25 is carrying a mutation of the cystic fibrosis transmembrane regulator protein (CFTR) which predisposes to the disease. With the advent of new treatment protocols and nutritional support most CF children can now expect to live up to adulthood, with a median age of survival of 47.7 years old (CCFF 2007 report). Above all, diagnosis through newborn screening can improve the disease outcomes by allowing earlier treatment of CF complications. However, it appears that CF newborn screening (CFNS) programs are not widely implemented especially in Canada. One of the main reasons is the lack of information regarding the choice about the best, i.e., the most cost/effective, screening option. This lack of information is not surprising considering the important number of possible options that exist due to the various available tests per se (e.g. biochemical or molecular tests, or a selected panel of mutations) and the various protocols (sequential, cascade, etc.) that are possible. The aim of this one-year research project is to identify, using simulations, the most cost/effective (C/E) and cost/utile (C/U) strategies for neonatal CF screening under various conditions of prevalence of mutations and costs of tests. This study should provide to public health authorities of Quebec and other interested provinces a valuable information regarding which type of CF screening is likely to be the most C/E and C/U if introduced in their jurisdiction.
Competitiondate
201009
Approvedterm2
1 yr 0 mth
Pinamesdelim
Reinharz, Daniel; Daigneault, Patrick
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $63,815~ $0~